Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 6—June 2005

Dispatch

Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031

Surbhi Malhotra-Kumar*Comments to Author , Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
Author affiliations: *University of Antwerp, Antwerp, Belgium

Main Article

Table A1

In vitro activity of 6 antimicrobial agents against macrolide-resistant Streptococcus pyogenes phenotypes during 1999–2003

Antimicrobial* Constitutive (n = 209)
M (n = 279)
Inducible (n = 18)
Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Erythromycin 4–>512 >512 >512 1–128 8 16 1–>512 4 >512
Clindamycin 2–>512 >512 >512 ≤0.03–4 0.06 1 0.125–256 0.75 128
Clarithromycin 1–>512 >512 >512 1–256 8 16 0.5–>512 2 >512
Azithromycin 4–>512 >512 >512 1–128 8 16 0.5–>512 4 >512
Tetracycline 0.06–128 32 64 ≤0.03–64 0.25 0.5 0.06–64 0.5 64
Telithromycin† 0.0075–32 1 8 0.0075–2 0.5 0.5 0.003–4 0.06 0.5

*Dilution range of 0.03 to 512 μg/mL for all antimicrobial agents except telithromycin, which is 0.00375 to 64 μg/mL.
†Breakpoints for telithromycin, susceptible ≤1μg/mL, resistant ≥4 μg/mL.

Main Article

1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.

TOP